文献速递妇科生殖医学

母亲多内分泌代谢性卵巢综合征与女婴微小青春期卵巢活动的关联

Associations of Maternal Polyendocrine Metabolic Ovarian Syndrome with Offspring Ovarian Activity in Minipuberty.
PubMed 文献 · Fertil Steril · 2026-10-05

本研究基于哥本哈根镇痛研究(COPANA)前瞻性队列,纳入298名女婴,评估母亲自报多内分泌代谢性卵巢综合征(PMOS)与女婴微小青春期卵巢活动的关联。结果显示,母亲PMOS与女婴卵巢体积增大43.48%、AMH升高0.55 SDS、SHBG升高0.61 SDS及内膜厚度减少0.03 cm相关。提示PMOS相关卵巢形态和功能改变可能在生命早期即已显现。

要点

  • 母亲PMOS与女婴微小青春期卵巢体积增大43.48%相关(p=0.05)。
  • PMOS暴露女婴AMH升高0.55 SDS(p=0.03),SHBG升高0.61 SDS(p=0.01)。
  • PMOS暴露女婴子宫内膜厚度减少0.03 cm(p=0.04)。

核心结论

  • 母亲PMOS与女婴微小青春期卵巢体积增大和AMH水平升高相关,提示PMOS相关卵巢改变可能在生命早期即已显现。

研究设计与样本

  • 前瞻性观察性妊娠与出生队列:哥本哈根镇痛研究(COPANA),2020-2022年于丹麦哥本哈根大学医院Rigshospitalet开展。
  • 纳入685名单胎孕妇,中位孕周13.7周(IQR 12.8-15.0);589名婴儿(302名女婴)在平均3.49±0.44月龄时接受检查。
  • 母亲PMOS基于既往医学诊断自报,经卵巢超声(n=8)或血液检测联合超声(n=14)确立;最终纳入298名有PMOS信息的女婴(是=22,否=276)。

主要发现

  • 调整模型显示,母亲自报PMOS与女婴卵巢体积增大43.48%(0.14; 105.58)相关,p=0.05。
  • PMOS暴露女婴AMH升高0.55 SDS(0.06; 1.04),p=0.03;SHBG升高0.61 SDS(0.15; 1.07),p=0.01。
  • PMOS暴露女婴子宫内膜厚度减少0.03 cm(-0.06; -0.00),p=0.04。
  • 母亲特征包括孕前BMI在组间无差异。

临床怎么用

  • 对于母亲有PMOS病史的女婴,在微小青春期可关注卵巢体积和AMH等指标的变化。
  • 目前发现为关联性,尚不能据此推荐常规筛查或干预,需结合临床个体化评估。

局限性

  • 母亲PMOS基于自报,仅部分经超声或血液检测确认,可能存在错分偏倚。
  • PMOS暴露组样本量较小(n=22),结果需谨慎解读。
  • 观察性设计不能推断因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study whether maternal PMOS is associated with altered ovarian activity in infant daughters during minipuberty. DESIGN: Prospective, observational pregnancy and birth cohort: The Copenhagen Analgesic Study (COPANA), conducted at Copenhagen University Hospital - Rigshospitalet, Denmark (2020-2022). SUBJECTS: Singleton pregnant women (n = 685) recruited at a median (IQR) gestational age of 13.7 weeks (12.8-15.0). Overall, 589 infants (302 girls) underwent examination during minipuberty at a mean age of 3.49 ± 0.44 months. EXPOSURE: Maternal PMOS was self-reported based on a previous medical diagnosis, established by ovarian ultrasound (n = 8) or combined blood tests and ultrasound (n = 14). Overall, 298 girls with available information on maternal self-reported PMOS status (yes = 22, no = 276) were included in this study. MAIN OUTCOME MEASURES: Ovarian and uterine morphology by transabdominal ultrasound scan and circulating levels of anti-Müllerian hormone (AMH), inhibin B, gonadotropins (immunoassays), steroid hormones (LC/MS-MS). Linear regression models were adjusted for maternal paracetamol and alcohol use during pregnancy, with sensitivity analysesfor maternal nicotine use. RESULTS: Maternal self-reported PMOS was associated with increased offspring ovarian volume: 43.48% (0.14; 105.58) using adjusted models, p = 0.05. PMOS-exposed daughters also had higher AMH: 0.55 SDS (0.06; 1.04), p = 0.03, higher SHBG: 0.61 SDS (0.15; 1.07), p = 0.01, and reduced endometrial thickness: -0.03 cm (-0.06; -0.00), p = 0.04. Maternal characteristics, including pre-pregnancy body mass index, did not differ between groups. CONCLUSION: Maternal PMOS was associated with larger ovarian volume and higher AMH levels in infant daughters, indicating that PMOS-related alterations in ovarian morphology and function may be evident already in early life.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Guttesen LF, Mola G, Frederiksen H, et al. Associations of Maternal Polyendocrine Metabolic Ovarian Syndrome with Offspring Ovarian Activity in Minipuberty. Fertil Steril. 2026. PMID: 42833544. doi:10.1016/j.fertnstert.2026.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。